Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Interview with Kushal Kadakia on the 21st Century Cures Act,...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
For many people, alopecia areata is a transient problem, in...
- Clinical Problem-Solving Looking Back L. Glick and Others
Treatment with allopurinol at a dose of 50 mg daily was...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Given the wide availability and low cost of ivermectin and...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
17 cze 2021 · A concentration dependent antiviral effect of ivermectin in COVID-19 was identified, with significant reductions in SARS-CoV-2 viral load in respiratory secretions among patients achieving high systemic ivermectin concentration compared to untreated controls.
30 mar 2024 · Despite no conclusive evidence or guidelines recommending ivermectin as a therapeutic drug for COVID-19, clinicians could use it with caution in the absence of better alternatives, and self-medication of ivermectin is not recommended for patients with COVID-19.
12 paź 2020 · The article by Ceplowicz Rajter et al1 published in CHEST (January 2021), which presents a significant effect of ivermectin at standard dose on COVID-19 mortality rates, raises once again important questions on the significance of observational studies that report posttreatment outcome for COVID-19.
14 gru 2022 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients who do...
ivermectin at standard dose on COVID-19 mortality rates, raises once again important questions on the significance of observational studies that report posttreatment outcome
1 sie 2024 · Authors assessed the efficacy and safety of ivermectin for people with confirmed COVID-19 using prospectively registered RCTs. Completed and ongoing RCTs until December 16, 2021, and RCTs with >1000 participants up to April 2022 were included.
